Japan continues to position itself as a global leader in regenerative medicine through its progressive regulatory framework tailored to the unique characteristics of cell, tissue, and gene therapy (CTGT) products....more
9/26/2025
/ Biologics ,
Biotechnology ,
Clinical Trials ,
Healthcare ,
Japan ,
Life Sciences ,
New Guidance ,
Pharmaceutical Industry ,
Regenerative Medicine ,
Regulatory Authority ,
Regulatory Oversight ,
Regulatory Requirements